alexa The T-body Approach Combining Antibody Specificity With T Cell Activity For Adoptive Vaccination Of Cancer
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd International Conference on Vaccines & Vaccination
July 29-31, 2013 Embassy Suites Las Vegas, NV, USA

Zelig Eshhar
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.016
Abstract
T he ?T-body? approach is based on engineered T cells expressing chimeric antibody receptor (CAR) that endows them with antibody-type specificity to any pre-defined target antigen. We have designed the modular CAR construct so that the modified, redirected T cells will undergo activation and perform their effector or regulatory function upon encountering their target. Accordingly, the CAR?s composition includes extracellular recognition domain made of a single chain variable fragment (scFv) of an antibody linked to intracellular domains of various stimulatory and co-stimulatory molecules that dictate the function of the transduced cells. For antitumor reactivity we constructed CARs made of scFv specific to human Her2/neu, CEA and CD24 (a cancer stem cell marker of certain adenocarcinomas such as pancreatic and colorectal ones). To optimize the antitumor effect in therapeutic settings we have treated either immunodeficient mice bearing human cancer xenografts or transgenic mice that spontaneously develop tumors expressing TAA. T-bodies effectively rejected primary as well as disseminated tumors. Multiple systemic administrations of T-bodies were required for complete elimination of xenografts and autologous murine tumors. Of note, single intratumoral injection was sufficient to eliminate breast, prostate cancer bone metastases as well as colorectal and pancreatic cancers. Moreover, under certain conditions, we have established a time-window which allows allogeneic T-bodies to serve as universal donors. Recently, our pioneering studies in murine models have been reproduced and applied in pilot trials to end-stage cancer patients. Dramatic complete responses have been already reported in neuroglioma, chronic lymphocyte leukemia, and acute child and adult B cell lymphoma patients. These trials have also reported on several treatment-related severe yet manageable side effects (mostly associated with acute ?cytokine-storm? and ?tumor lysis? syndrome, both outcomes of the vigorous antitumor responses of the T-bodies that could eliminate a huge tumor mass within the first few weeks treatment. The dynamics of the T-body antitumor effect reflect both their built-in ability to specifically recognize the tumor, propagate and reject it and further differentiate into memory cells that keep the tumor on-check
Biography
Zelig Eshhar has completed his Ph.D. at the Weizmann Institute and post doctoral studies from Harvard University Medical School. He spent sabbatical years of research at DNAX Institute of Molecular Biology and Stanford University and at the National Cancer Institute at the NIH. He served as the Chairman of the Department of Immunology at the Weizmann Institute and holds the position of Chairman of research in Immunology Tel Aviv Sourasky Medical Center and guest Professor at the Faculty of Medicine of Tel Aviv University. He has published more the 210 research articles.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]csonline.com

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords